ESA’s Part D Coverage Feels Trickle-Down Effect Of Part B Restrictions
All of the attention being paid to erythropoiesis-stimulating agents in Medicare Part B is beginning to spill over into Part D
You may also be interested in...
Despite the emergence of safety concerns related to use of erythropoiesis-stimulating agents in recent years, the American Society of Hematology and the American Society of Clinical Oncology are essentially providing the same dosing recommendations in their latest guideline for treatment of chemotherapy-induced anemia as in the previous version from five years ago
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.